Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 701 - 750 out of 45,506

Document Document Title
WO/2013/129603
The present invention addresses the problem of developing and providing a method for designating a disease that relates to the amount of TDP-43 existing in cells and a method for producing a TDP-43 binding inhibitor. By collecting cells ...  
WO/2013/129739
The present invention relates to a pharmaceutical composition comprising, as an active ingredient, a polypeptide which contains a bee venom-phospholipase A2 (BV-PLA2) amino acid sequence without a leader sequence for treating or preventi...  
WO/2013/130150  
WO/2013/127917
The present invention relates to compositions and methods for the treatment of amyotrophic lateral sclerosis. More specifically, the present invention relates to novel combinatorialtherapiesfor treating amyotrophic lateral sclerosisor a ...  
WO/2013/127817
This invention is directed to compounds (I), which are PDE10A enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acce...  
WO/2013/127293
Provided are a culture medium for preparing neural stem cells and use thereof, the culture medium for preparing neural stem cells comprising: a basic culture medium suitable for the growth of stem cells, and a cell signal pathway inhibit...  
WO/2013/130422
The invention described herein relates to methods for treating mitochondrial diseases. In particular, the invention relates to methods for treating mitochondrial diseases by administering therapeutically effective amounts of one or more ...  
WO/2013/128088
The present invention relates to the use of modafinil in cocaine addiction. The modafinil used is the dextrorotatory enantiomer thereof (modafinil S), having a very rapid release time of less than 1 hour, preferably 15-30 minutes, and ve...  
WO/2013/127345
Provided are compounds as protein kinase inhibitors and use thereof. Preparation methods of the compounds are also provided. The compounds can effectively inhibit the activities of protein kinases and proliferation of abnormal activated ...  
WO/2013/128562
[Problem] To provide an adhesive skin patch containing rivastigmine, in which desired adhesion performance can be achieved satisfactorily and rivastigmine can exist highly stably for a long period without using any antioxidative agent, a...  
WO/2013/129085
The present invention provides a circadian rhythm-improving agent containing lactic acid bacteria or a processed product thereof as an active ingredient.  
WO/2013/124816
A method of generating neural stem cells or motor neurons is disclosed, the method comprising up-regulating a level of at least one exogenous miRNA and/or down-regulating at least one miRNA using an agent which hybridizes to the miRNA in...  
WO/2013/124416
The present invention relates to a calcineurin inhibitor for use in the treatment of a lesional vestibular disorder.  
WO/2013/124026
Compounds of the formula I in which R1, R2 and R4 have the meanings indicated in Claim 1, are inhibitors of Syk, and can be employed, inter alia, for the treatment of cancer, rheumatoid arthritis and / or systemic lupus  
WO/2013/125878
The present invention relates to: a method for regulating the differentiation of neural stem cells or neural progenitor cells into dopaminergic neurons, comprising the step of increasing or inhibiting the activity of ADAM17 and/or ADAM10...  
WO/2013/124815
A method of qualifying a mesenchymal stem cell (MSC) population is disclosed. The method comprises: (a) ex vivo differentiating a population of mesenchymal stem cells originating from the subject towards a first lineage - specific cell, ...  
WO/2013/125617
This solid pharmaceutical composition is useful as a solid pharmaceutical composition of 1-(3-(2-(1-benzothiophen-5-yl) ethoxy) propyl) azetidin-3-ol, which is excellently elutable and moldable and is stable in long-term storage, or a sa...  
WO/2013/126205
Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of mixed monoamine reuptake inhibitor locally at or near a target site, one can relieve pain caused by diverse sour...  
WO/2013/125634
 Provided are a TLR4 agent, a tissue homeostasis agent, a hepatocyte growth factor inducer, a tissue repairing agent, and a sirtuin inducer using hyaluronic acid fragments. Hyaluronic acid fragments selected from sizes of 2-20 sugar ...  
WO/2013/123766
The present invention relates to a phosphodiesterase 4 inhibitor capable of avoiding vomiting. Formula (I) represents a compound or a prodrug or a solvate, R1 is an independent methoxy, bromine and substituted aryl; X is an optionally su...  
WO/2013/123824
Provided are a polyglycol - naloxone conjugate of general formula (II) and a pharmaceutical composition containing the conjugate. In the conjugate, n is an integer of 1 - 20. Also provided is a conjugate of three - branched or four - bra...  
WO/2013/124158
The present invention relates to the 1 H-indazole-3-carboxamide compounds having the following general formula (I) as glycogen synthase kinase 3 beta (GSK-3ß) inhibitors and to their use in the treatment of GSK-3p-related disorders such...  
WO/2013/125225
The invention aims to provide a composition for treating atopic dermatitis, bronchial asthma, allergic rhinitis or major depressive disorder (depression), comprising a mixture of Formula antidoti coptidis (orengedokuto) and Formula reple...  
WO/2013/124341
The present invention relates to new substituted pyrazolo[1,5-a]pyridine having a great affinity for sigma receptors, especially sigma-1 receptor, as well as to the process for the preparation thereof, to compositions comprising them, an...  
WO/2013/124817
A method of generating a population of cells useful for treating a nerve disease or disorder in a subject, the method comprising up-regulating a level of at least one exogenous miRNA in mesenchymal stem cells (MSCs) and/or down-regulatin...  
WO/2013/125531
For the purpose of providing a composition, which can effectively ameliorate various sequelae caused by central nerve damage, and a use of the composition, a composition that contains a compound having a CD3 agonistic activity is used.  
WO/2013/124413
The present invention relates to new thiadiazolidmediones of formula (I), or any pharmaceutically acceptable salt, solvate or prodrug thereof, and its use in the treatment of a disease in which glycogen synthase kinase 3 (GSK-3) is invol...  
WO/2013/125543
Provided is a prophylactic or therapeutic agent for autoimmune diseases (e.g., psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus), which ha...  
WO/2013/125135
Provided is an anthocyanin-containing composition which enhances the bioabsorbability of anthocyanins, which have low bioavailability, causes anthocyanins to be more effectively absorbed in vivo, and enhances absorption of anthocyanins i...  
WO/2013/124169
1 H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors. The present invention relates to the 1 H-indazole-3-carboxamide compounds for use as glycogen synthase kinase 3 beta (GSK-33) inhibitors and to their use...  
WO/2013/125722
Provided is a neuroprotective agent screening method comprising an administration step for administering glucose and a test substance to a hypoglycemic encephalopathy model, which is a non-human animal having a flat electroencephalogram ...  
WO/2013/124026
Compounds of the formula I in which R1, R2 and R4 have the meanings indicated in Claim 1, are inhibitors of Syk, and can be employed, inter alia, for the treatment of cancer, rheumatoid arthritis and / or systemic lupus  
WO/2013/122178
 The purpose of the present invention is to use a protein obtained by fusing a cancer-specific antigen and a cytokine as a prophylactic or therapeutic agent for cancer. A pharmaceutical composition for preventing or treating cancer, ...  
WO/2013/122029
The purpose of the present invention is to provide an aromatic ring compound exhibiting GPR40 agonist activity. The compound represented by formula (I) (refer to the description for information pertaining to each symbol in the formula) o...  
WO/2013/121440
The present invention discloses process for preparing benzisothiazol-3-yl- piperazin-l-yl-methyl-cyclo hexyl-methanisoindol-l,3-dione and intermediates thereof.  
WO/2013/122107
The present invention relates to: a compound represented by formula (1) or a pharmaceutically acceptable salt thereof; a pharmaceutical composition which contains, as an active ingredient, the compound or a pharmaceutically acceptable sa...  
WO/2013/122408
The present invention relates to the pharmaceutical use of FAM19A5 involved in regulating gliogenesis and, more specifically, to the use of FAM19A5 in the prevention, diagnosis, or treatment of central nervous system injuries, degenerati...  
WO/2013/122778
Disclosed is a method of treating or preventing a disease or disorder of the central nervous system (CNS) in a patient comprising administering transcranially, for example, directly to the skull, an effective amount of an anti-inflammato...  
WO/2013/120379
Provided in the present invention is the use of SBT in the preparation of an inhibitor of GSK-3β, and in particular in the preparation of medicines for preventing and treating Alzheimer's disease and senescence.  
WO/2013/122502
The invention relates to the field of medicine. The pharmaceutical composition for the treatment of neurodegenerative diseases, in particular amyotrophic lateral sclerosis, contains non-replicating nanoparticles which comprise the human ...  
WO/2013/120835
The present invention relates to isoindoline derivatives of the formula (I) or a physiologically tolerated salt thereof. The present invention also relates to pharmaceutical compositions comprising such isoindoline derivatives, and the u...  
WO/2013/120229
Disclosed is a method for preparing aqueous nanoparticle suspensions of derivatives of 4,9-dihydroxy-naphtho[2,3-b]furan aliphatic acid esters. The compositions and the uses of the aqueous nanoparticle suspensions prepared according to t...  
WO/2013/120896
The present invention relates to a compound for use in the prevention and/or treatment of a disease selected from a neurodegenerative disease, especially Alzheimer disease, and a disease, disorder or condition involving an activation of ...  
WO/2013/120980
The invention relates to novel compounds of Formula I: wherein A1, A2, A3, A4, A5, A6, R2, R4, R5, R6, R7, R8 and subscripts m and n each has the meaning as described herein. Compounds of Formula I and pharmaceutical compositions thereof...  
WO/2013/121334
The present invention relates to compounds of formula I, use of these compounds to treat mental and neurological disorders, especially depressions and psychoses of different etiology and methods for their preparation. The compounds provi...  
WO/2013/123083
Disclosed herein is use of one or more aminopyridines in methods and compositions for treatment of impairments in gait or balance in patients with multiple sclerosis.  
WO/2013/120438
Disclosed is the use of an inverse agonist for α-subunit-containing γ-aminobutyric acid A receptor in the preparation of a medicine for the prevention, alleviation, or treatment of pain.  
WO/2013/118858
It is achieved successfully to obtain a polypeptide having improved stability compared with that of a parent polypeptide thereof by modifying at least one amino acid residue located in a loop domain in an Fc region of an antibody. In add...  
WO/2013/119794
Modified release formulations of viloxazine and methods of administering the same are disclosed. High- drug load formulations of viloxazine are further disclosed.  
WO/2013/119042
The present invention provides a composition for preventing and curing of neuropathic pain, comprising substance P. Substance P of the present invention shows mitigating, preventive and/or therapeutic effects on neuropathic pain.  

Matches 701 - 750 out of 45,506